3-羟基双环[4.2.0]辛-1,3,5-三烯-7-甲腈 | 242473-46-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 3-羟基双环[4.2.0]辛-1,3,5-三烯-7-甲腈
• 英文名称: 4-hydroxybenzocyclobutene-1-carbonitrile
• 英文别名: 1,2-dihydroxy-4-hydroxybenzocyclobutene-1-carbonitrile；3-hydroxybicyclo[4.2.0]octa-1,3,5-triene-7-carbonitrile；1-cyano-4-hydroxybenzocyclobutane；3-hydroxybicyclo[4.2.0]octa-1(6),2,4-triene-7-carbonitrile
• CAS: 242473-46-7
• 化学式: C₉H₇NO
• 分子量: 145.161
• InChiKey: RERGCZPHSRRDGN-UHFFFAOYSA-N

物化性质

• 熔点：
  110-112 °C
• 沸点：
  378.5±42.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  44
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-羟基双环[4.2.0]辛-1,3,5-三烯-7-甲腈 在 palladium on activated charcoal 正丁基锂 、 四丙基高钌酸铵 、 4 A molecular sieve 、 氢气 、 二异丁基氢化铝 、 N-甲基吗啉氧化物 、 过碘酸 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 邻二氯苯 为溶剂， 反应 52.08h， 生成 7-hydroxy-3a-methyl-1,2,3a,4,5,9b-hexahydro-3H-cyclopenta[a]naphthalen-3-one
  参考文献：
  名称：

  实用的不对称合成反式-4,5-Benzhydrindan-1-ones作为A-Nor B-芳族类固醇化合物的前体

  摘要：

  的对映体控制合成反式-4,5- benzhydrindan -1-酮是由立体选择性的手段[4 + 2]环加成实现ö -quinodimethanes由苯并环丁烯衍生物作为一个关键步骤的热裂解产生。热反应的手性底物是通过非对映选择性格氏试剂加到与苯并环丁烯环相连的手性O-异亚丙基甘油基酮上而合成的，它们是简单地由d-甘露醇作为手性来源制备的。这种方法可以为A-或B-芳族甾族化合物提供新的有效途径。

  DOI：

  10.1021/jo051060w
• 作为产物：
  描述：

  3-(2-溴-5-甲氧基苯基)丙腈 在 aluminum (III) chloride 、 正十二烷基甲基硫醚 、 氨 、 sodium amide 作用下， 以 甲苯 为溶剂， 反应 4.0h， 生成 3-羟基双环[4.2.0]辛-1,3,5-三烯-7-甲腈
  参考文献：
  名称：

  Identification of Fused-Ring Alkanoic Acids with Improved Pharmacokinetic Profiles that Act as G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonists

  摘要：

  The G protein-coupled receptor 40 (GPR40)/free fatty acid receptor 1 (FFA1) has emerged as an attractive target for a novel insulin secretagogue with glucose dependency. We previously identified phenylpropanoic acid derivative 1 (3-{4-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-2-fluorophenyl}propanoic acid) as a potent and orally available GPR40/FFA1 agonist; however, 1 exhibited high clearance and low oral bioavailability, which was likely due to its susceptibility to beta-oxidation at the phenylpropanoic acid moiety. To identify long-acting compounds, we attempted to block the metabolically labile sites at the phenylpropanoic acid moiety by introducing a fused-ring structure. Various fused-ring alkanoic acids with potent GPR40/FFA1 activities and good PK profiles were produced. Further optimizations of the lipophilic portion and the acidic moiety led to the discovery of dihydrobenzofuran derivative 53 ((6-{[4'-(2-ethoxyethoxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-2,3-dihydro-1-benzofuran-3-yl)acetic acid), which acted as a GPR40/FFA1 agonist with in vivo efficacy during an oral glucose tolerance test (OGTT) in rats with impaired glucose tolerance.

  DOI：

  10.1021/jm2012968

文献信息

• 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them
  申请人：Peglion Jean-Louis

  公开号：US20090069296A1

  公开（公告）日：2009-03-12

  Compounds of formula (I): wherein: R 1 represents a hydrogen atom or a group selected from cycloalkyl, benzyl and optionally substituted alkyl, R 2 , R 3 , R 4 and R 5 each represent a hydrogen atom or a hydroxy, methyl, —OSO 2 R 10 , —OCOR 10 or optionally substituted alkoxy group, or R 2 and R 3 , or R 3 and R 4 , or R 4 and R 5 together form a group —O—(CH 2 ) q —O—, —O—CH═CH—O— or —O—CH═CH—, R 6 , R 7 , R 8 and R 9 each represent a hydrogen atom or an alkoxy group, or R 6 and R 7 , or R 7 and R 8 , or R 8 and R 9 together form a group —O—(CH 2 ) q —O—-, R 10 represents a group selected from linear or branched C 1 -C 6 alkoxy, NR 11 R′ 11 and optionally substituted alkyl, R 11 and R′ 11 each represent a hydrogen atom or an alkyl group, or R 11 and R′ 1 together with the nitrogen atom carrying them form an optionally substituted, monocyclic or bicyclic, nitrogen-containing heterocycle, X represents O, NH or CH 2 , m and p each represent 0 or 1, n and q each represent 1 or 2, in racemic form or in the form of optical isomers,and also addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in treating various pathologies.

  式（I）的化合物： 其中： R1代表氢原子或从环烷基、苄基和可选择地取代的烷基中选择的基团， R2、R3、R4和R5分别代表氢原子或羟基、甲基、—OSO2R10、—OCOR10或可选择地取代的烷氧基，或R2和R3，或R3和R4，或R4和R5一起形成一个基团—O—（CH2）q—O—，—O—CH═CH—O—或—O—CH═CH—， R6、R7、R8和R9分别代表氢原子或烷氧基，或R6和R7，或R7和R8，或R8和R9一起形成一个基团—O—（CH2）q—O—-， R10代表从线性或支链C1-C6烷氧基、NR11R′11和可选择地取代的烷基中选择的基团， R11和R′11分别代表氢原子或烷基基团，或R11和R′1与携带它们的氮原子一起形成一个可选择地取代的、单环或双环、含氮杂环， X代表O、NH或CH2， m和p各自代表0或1， n和q各自代表1或2， 以外消旋形式或光学异构体形式，以及其与药学上可接受的酸的加合盐。 含有这些化合物的药物，对治疗各种病理有用。
• Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds
  申请人：——

  公开号：US20020019380A1

  公开（公告）日：2002-02-14

  A compound selected from those of formula (I): 1 wherein: overscore (_____)} denotes single bond or double bond, n is integer from 1 to 6 inclusive, R 1 , and R 2 represent a group selected from hydrogen, linear or branched (C 1 -C 6 )-alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl, X represents a group selected from —CH═CH—, oxygen, S(O) m wherein m is integer from 0 to 2 inclusive, and NR 3 wherein R 3 represents a group as defined in the description, Y represents CH or CH 2 depending on whether _____ denotes single bond or double bond, or may have the additional meaning of oxygen when X represents oxygen, T represents monocyclic or polycyclic (C 3 -C 10 )cycloalkyl optionally containing within the ring system oxygen, selenium, S(O) p , NR 3 , or SiR 4 R 5 wherein p, R 3 , R 4 , and R 5 are as defined in the description, its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful in the treatment of CNS disorders.

  从以下通式（I）的化合物中选择的一种化合物：1其中：overscore (_____)}表示单键或双键，n是1至6（含）的整数，R1和R2表示从氢、直链或支链（C1-C6）-烷基、芳基、芳基烷基、环烷基、环烷基烷基、烯基、炔基、杂环烷基、杂环烷基烷基、杂芳基和杂芳基烷基中选择的基团，X表示从—CH═CH—、氧、S(O)m（其中m是0至2（含）的整数）和NR3（其中R3表示如说明书中定义的基团）中选择的基团，Y表示CH或CH2取决于_____表示单键或双键，或者当X表示氧时，Y还可以有氧的含义，T表示含或不含环系统内氧、硒、S(O)p、NR3或SiR4R5的单环或多环（C3-C10）环烷基（其中p、R3、R4和R5如说明书中定义），其异构体和与药学上可接受的酸或碱形成的加成盐，以及含有这些化合物的药物制剂，可用于治疗中枢神经系统疾病。
• [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2010080503A1

  公开（公告）日：2010-07-15

  In one aspect, the present invention provides for a compound of Formula I; in which the variable X1a, X1b, X1c, X1d, Q, A, R1, B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.

  在一个方面，本发明提供了一种具有式I的化合物；其中变量X1a、X1b、X1c、X1d、Q、A、R1、B、L、E和下标m和n的含义如本文所述。在另一个方面，本发明提供了包括式I化合物的药物组合物，以及使用式I化合物治疗由Bcl-2抗凋亡蛋白（例如抗凋亡Bcl-xL蛋白）的表达或过度表达所特征的疾病和状况（例如癌症、血小板增多症等）的方法。
• Benzocyclobutane compounds
  申请人：Adir et Compagnie

  公开号：US06107345A1

  公开（公告）日：2000-08-22

  A compound of formula (I): ##STR1## wherein: Z.sub.1, Z.sub.2, Z.sub.3, Z.sub.4, which may be identical or different, represent a group as defined in the description, X represents oxygen, S(O).sub.p, --(CH.sub.2).sub.n -- or --CH.sub.2 --Y--CH.sub.2 -- wherein p, n and Y are as defined in the description, A represents ##STR2## wherein m, R.sub.1, R.sub.2 and G are as defined in the description, their isomers and addition salts thereof with a pharmaceutically-acceptable acid, and medicinal products containing the same are useful in the treatment of diseases like depression, panic attacks, obsessive compulsive disorders, phobias, impulsive disorders, drug abuse or anxiety.

  式(I)的化合物：其中：Z₁，Z₂，Z₃，Z₄，可以相同也可以不同，表示如描述中定义的基团，X表示氧、S(O)ₚ、--(CH₂)ₙ--或--CH₂--Y--CH₂--其中p，n和Y如描述中定义，A表示其中m，R₁，R₂和G如描述中定义，它们的异构体及其与药用可接受的酸的加合盐，以及含有它们的药物产品在治疗抑郁症、恐慌发作、强迫性障碍、恐惧症、冲动障碍、药物滥用或焦虑等疾病方面是有用的。
• Synthesis of a New Class of Furan-Fused Tetracyclic Compounds Using <i>o</i>-Quinodimethane Chemistry and Investigation of Their Antiviral Activity
  作者：Yuji Matsuya、Kazushige Sasaki、Mamiko Nagaoka、Hiroko Kakuda、Naoki Toyooka、Nobuko Imanishi、Hiroshi Ochiai、Hideo Nemoto

  DOI：10.1021/jo0486995

  日期：2004.11.1

  evaluation of antiviral activity of new furan-fused tetracyclic compounds are described. The syntheses were satisfactorily achieved on the basis of o-quinodimethane chemistry, using furan-containing benzocyclobutene derivatives as a substrate, in high generality and stereoselectivity. The various derivatives thus synthesized were examined on their inhibitory activity on virus growth using a hemagglutinin

  描述了新型呋喃稠合的四环化合物的合成和抗病毒活性评估。以邻呋喃二甲烷化学为基础，以含呋喃的苯并环丁烯衍生物为底物，具有很高的通用性和立体选择性，可以令人满意地完成合成。使用血凝素（HA）方法检查了由此合成的各种衍生物对病毒生长的抑制活性，从而发现了具有高活性和良好治疗指数的新型抗病毒药物的有前途的候选物。